Sofdra Safety Data Show Low Serious Adverse Event Rate

A JAAD brief report analyzing postmarketing data finds serious drug-related adverse events affected 0.08% of Sofdra's patient population.

Updated on Nov. 17, 2026 in Beauty

Gouache-painted editorial illustration of a plain unlabeled tube of gel standing on a cream surface, offering a quiet, reassuring still life about a treatment for excessive underarm sweating.
A peer-reviewed JAAD brief report found serious drug-related adverse events affected 0.08% of patients using Botanix Pharmaceuticals' Sofdra gel for underarm sweating. AI Illustration. Upload story photo >

The Journal of the American Academy of Dermatology published a peer-reviewed brief report analyzing postmarketing safety data for Sofdra, a topical gel approved for primary axillary hyperhidrosis. Botanix Pharmaceuticals announced the publication, which covers spontaneously reported adverse events from June 18, 2024, to January 31, 2026.

Why it matters

The report offers a real-world view of safety after approval, complementing pivotal trial results in which no drug-related serious adverse events were observed. Patients and prescribers considering treatment for excessive underarm sweating can weigh these postmarketing findings alongside trial data.

The analysis covered 20,667 prescriptions filled and 249 drug-related adverse events, of which 16 serious reports encompassing 29 events were identified. Spontaneous reporting cannot by itself establish how often these events are caused by the drug.

The players

Botanix Pharmaceuticals Limited

An Australian pharmaceutical company listed on the Australian Securities Exchange under the ticker BOT, which holds the rights to Sofdra.

The details

Authors analyzed spontaneously reported adverse event data from US healthcare providers and consumers, documenting 194 reports involving 431 adverse events. No drug-related serious adverse events were observed during the pivotal phase 3 trials.

Timeline

  1. June 18, 2024: Postmarketing adverse event analysis period begins.

  2. January 31, 2026: Postmarketing adverse event analysis period ends.

  3. November 16, 2026: Botanix announces the JAAD publication.

Health Landscape

The FDA approval of Sofdra for primary axillary hyperhidrosis in nine-year-olds and older set the labeled population for this topical treatment. This JAAD report extends the safety record from pivotal trials into a broader postmarketing population.

For people with excessive underarm sweating, the report indicates serious drug-related events were uncommon after approval, though the data do not establish causation. Patients should discuss the labeled uses, observed side effects, and their own risk profile with a clinician before starting treatment.

The takeaway

Postmarketing reports provide a useful check on trial findings, though they cannot by themselves confirm how often a drug causes a given event. Readers weighing topical treatments for sweating should compare trial data with real-world safety reports and consult a clinician.

Further reading

Explore more on Beauty trends and product safety in the United States.

Source note: This article includes information reported by Finance News Network.